Key facts
- It has raised $13.8M; the latest was Later Stage VC in Sep 2025.
- Notable investors include Anhui Investment Group Holdings, Guangzhou Yuexiu Industrial Investment Fund Management, Hangzhou Huafang Chuangliang Investment Management, Shaanxi Growth Enterprise Guide Fund, Win-Win Capital — 9 tracked in total.
- Status: Privately Held (backing).
Investors
9- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Rongcan Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Rongcan Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Rongcan Biotech
Developer of mRNA-based pharmaceutical products designed for nucleic acid-based therapeutics. The company strives to become a whole-industry-chain company that covers from mRNA sequential design and synthesis, and LNP-based delivery systems to finished mRNA-based pharmaceutical products, enabling patients with efficient drug delivery.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2020
- Website
- rc-rna.com/
- Ownership
- Privately Held (backing)
Rongcan Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Rongcan Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Rongcan Biotech in its N-PORT filings yet. We sweep new filings monthly.